First Time Loading...

IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 37.62 USD -6.35% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

IDYA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. [ Read More ]

The intrinsic value of one IDYA stock under the Base Case scenario is 9.42 USD. Compared to the current market price of 37.62 USD, IDEAYA Biosciences Inc is Overvalued by 75%.

Key Points:
IDYA Intrinsic Value
Base Case
9.42 USD
Overvaluation 75%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
IDEAYA Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IDYA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
IDEAYA Biosciences Inc

Provide an overview of the primary business activities
of IDEAYA Biosciences Inc.

What unique competitive advantages
does IDEAYA Biosciences Inc hold over its rivals?

What risks and challenges
does IDEAYA Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in IDEAYA Biosciences Inc recently?

Summarize the latest earnings call
of IDEAYA Biosciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for IDEAYA Biosciences Inc.

Provide P/S
for IDEAYA Biosciences Inc.

Provide P/E
for IDEAYA Biosciences Inc.

Provide P/OCF
for IDEAYA Biosciences Inc.

Provide P/FCFE
for IDEAYA Biosciences Inc.

Provide P/B
for IDEAYA Biosciences Inc.

Provide EV/S
for IDEAYA Biosciences Inc.

Provide EV/GP
for IDEAYA Biosciences Inc.

Provide EV/EBITDA
for IDEAYA Biosciences Inc.

Provide EV/EBIT
for IDEAYA Biosciences Inc.

Provide EV/OCF
for IDEAYA Biosciences Inc.

Provide EV/FCFF
for IDEAYA Biosciences Inc.

Provide EV/IC
for IDEAYA Biosciences Inc.

Show me price targets
for IDEAYA Biosciences Inc made by professional analysts.

What are the Revenue projections
for IDEAYA Biosciences Inc?

How accurate were the past Revenue estimates
for IDEAYA Biosciences Inc?

What are the Net Income projections
for IDEAYA Biosciences Inc?

How accurate were the past Net Income estimates
for IDEAYA Biosciences Inc?

What are the EPS projections
for IDEAYA Biosciences Inc?

How accurate were the past EPS estimates
for IDEAYA Biosciences Inc?

What are the EBIT projections
for IDEAYA Biosciences Inc?

How accurate were the past EBIT estimates
for IDEAYA Biosciences Inc?

Compare the revenue forecasts
for IDEAYA Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of IDEAYA Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of IDEAYA Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of IDEAYA Biosciences Inc compared to its peers.

Compare the P/E ratios
of IDEAYA Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing IDEAYA Biosciences Inc with its peers.

Analyze the financial leverage
of IDEAYA Biosciences Inc compared to its main competitors.

Show all profitability ratios
for IDEAYA Biosciences Inc.

Provide ROE
for IDEAYA Biosciences Inc.

Provide ROA
for IDEAYA Biosciences Inc.

Provide ROIC
for IDEAYA Biosciences Inc.

Provide ROCE
for IDEAYA Biosciences Inc.

Provide Gross Margin
for IDEAYA Biosciences Inc.

Provide Operating Margin
for IDEAYA Biosciences Inc.

Provide Net Margin
for IDEAYA Biosciences Inc.

Provide FCF Margin
for IDEAYA Biosciences Inc.

Show all solvency ratios
for IDEAYA Biosciences Inc.

Provide D/E Ratio
for IDEAYA Biosciences Inc.

Provide D/A Ratio
for IDEAYA Biosciences Inc.

Provide Interest Coverage Ratio
for IDEAYA Biosciences Inc.

Provide Altman Z-Score Ratio
for IDEAYA Biosciences Inc.

Provide Quick Ratio
for IDEAYA Biosciences Inc.

Provide Current Ratio
for IDEAYA Biosciences Inc.

Provide Cash Ratio
for IDEAYA Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for IDEAYA Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for IDEAYA Biosciences Inc?

What is the current Free Cash Flow
of IDEAYA Biosciences Inc?

Financials

Balance Sheet Decomposition
IDEAYA Biosciences Inc

Current Assets 532.6m
Cash & Short-Term Investments 525.1m
Receivables 18k
Other Current Assets 7.5m
Non-Current Assets 116.7m
Long-Term Investments 107.5m
PP&E 8.4m
Other Non-Current Assets 782k
Current Liabilities 27.1m
Accounts Payable 6.6m
Accrued Liabilities 20.5m
Non-Current Liabilities 1.1m
Other Non-Current Liabilities 1.1m
Efficiency

Earnings Waterfall
IDEAYA Biosciences Inc

Revenue
23.4m USD
Operating Expenses
-157.8m USD
Operating Income
-134.4m USD
Other Expenses
21.5m USD
Net Income
-113m USD

Free Cash Flow Analysis
IDEAYA Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

IDYA Profitability Score
Profitability Due Diligence

IDEAYA Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Declining ROE
Declining ROIC
20/100
Profitability
Score

IDEAYA Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

IDYA Solvency Score
Solvency Due Diligence

IDEAYA Biosciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

IDEAYA Biosciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IDYA Price Targets Summary
IDEAYA Biosciences Inc

Wall Street analysts forecast IDYA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IDYA is 53.96 USD with a low forecast of 50.5 USD and a high forecast of 63 USD.

Lowest
Price Target
50.5 USD
34% Upside
Average
Price Target
53.96 USD
43% Upside
Highest
Price Target
63 USD
67% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IDYA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IDYA Price
IDEAYA Biosciences Inc

1M 1M
-15%
6M 6M
+45%
1Y 1Y
+153%
3Y 3Y
+105%
5Y 5Y
+236%
10Y 10Y
+236%
Annual Price Range
37.62
52w Low
14.56
52w High
47.13
Price Metrics
Average Annual Return 19.92%
Standard Deviation of Annual Returns 51.22%
Max Drawdown -75%
Shares Statistics
Market Capitalization 2.8B USD
Shares Outstanding 74 560 304
Percentage of Shares Shorted 12.74%

IDYA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.8B USD

Dividend Yield

0%

Description

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-05-23. The firm is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.

Contact

CALIFORNIA
South San Francisco
7000 Shoreline Ct Ste 350
+16504436209.0
https://www.ideayabio.com/

IPO

2019-05-23

Employees

81

Officers

President, CEO & Director
Mr. Yujiro S. Hata
Chief Scientific Officer
Dr. Michael A. White Ph.D.
Chief Medical Officer
Dr. Darrin M. Beaupre M.D., Ph.D.
Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations
Mr. Andres Ruiz Briseno CPA
Chief Technology Officer
Dr. Paul A. Barsanti Ph.D.
Chief Legal Officer & Company Secretary
Mr. Jason S. Throne Esq., J.D.
Show More
Chief of Staff & Clinical Development
Mr. Mick O'Quigley
Show Less

See Also

Discover More
What is the Intrinsic Value of one IDYA stock?

The intrinsic value of one IDYA stock under the Base Case scenario is 9.42 USD.

Is IDYA stock undervalued or overvalued?

Compared to the current market price of 37.62 USD, IDEAYA Biosciences Inc is Overvalued by 75%.